



Please scan this QR Code to view the Red Herring Prospectus and Abridged Prospectus

COMMON BID CUM APPLICATION FORM

ABH HEALTHCARE LIMITED - INITIAL PUBLIC ISSUE - NR

Registered Office: Anil Baghi Road, Ferozepur, Punjab - 152002, India.
Tel No.: +91 7888690018; E-mail: investor@anilbaghihospital.com; Website: www.abhhealthcare.org
Contact person: Mr. Rahul Sharma, Company Secretary & Compliance Officer;
Corporate Identity Number: U85300PB2021PLC052886

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIS, FPIs, FVCIS AND REGISTERED MULTI LATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS ETC. APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors
ABH HEALTHCARE LIMITED

100% BOOK BUILT ISSUE
ISIN: INE1R2M01019

Bid cum
Application
Form No.

SYNDICATE MEMBER'S STAMP & CODE	SUB-SYNDICATE MEMBER/ REGISTERED BROKERS/SCSB/CDP/RTA STAMP & CODE	1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER Mr. /Ms./M/s. _____ Address _____ Email _____ Tel. No. (with STD code) / Mobile _____
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS	☐ NSDL ☐ CDSL	6. INVESTOR STATUS ☐ Non-Resident Indian(s) (Repatriation basis) - NRI ☐ Registered Bilateral and Multilateral Development Financial Institutions - RBM ☐ Foreign Venture Capital Investor - FVCI ☐ Foreign Portfolio Investor - FPI ☐ All entities other than QIBs, Bodies Corporate and Individuals - NOH ☐ Other - OTH
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID		

4. BID OPTIONS	No. of Equity Shares Bid (In Figures) (Bids must be in Multiples of Bid Lot as advertised)	Price per Equity Share (₹) (Price in multiples of ₹ 1 only) (In Figures only)														
		Bid Price			Individual Discount			Net Price								
		8	7	6	5	4	3	2	1	3	2	1	3	2	1	
Option 1																
(OR) Option 2																
(OR) Option 3																

Please note that applications must be made in minimum of 2,400 Equity Shares and further multiples of 1,200 Equity Shares accordingly.

7. PAYMENT DETAILS [IN CAPITAL LETTERS]	PAYMENT OPTION: FULL PAYMENT ☒
Amount blocked (₹ in figures) _____ (₹ in words) _____	
ASBA Bank A/c No. _____	
Bank Name & Branch _____	
OR	
UPI ID (Maximum 45 characters) _____	

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC ISSUES ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDER'S UNDERTAKING' AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THIS COMMON BID CUM APPLICATION FORM GIVEN OVERLEAF.

8A. SIGNATURE OF SOLE/ FIRST BIDDER	8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)	8C. MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)
	I/We authorise the SCSB to do all acts as are necessary to make the application in the Issue. 1) _____ 2) _____ 3) _____	
Date : _____, 2026		

TEAR HERE



Please scan this QR Code to view the Red Herring Prospectus and Abridged Prospectus



ABH HEALTHCARE LIMITED
INITIAL PUBLIC ISSUE - NR

Acknowledgement Slip for
Members of the Syndicate / Sub-Syndicate
Members / Registered Broker /
SCSB / CDP / RTA / Agent

Bid cum
Application
Form No.

DPID / CL. ID		PAN of Sole / First Bidder	
Amount blocked (₹ in figures)	ASBA Bank A/c No./UPI ID	Stamp and Signature of SCSB Branch	
Bank Name & Branch			
Received from Mr./Ms./M/s. _____			
Telephone / Mobile	Email		

TEAR HERE

ABH HEALTHCARE LIMITED INITIAL PUBLIC ISSUE - NR		Option 1	Option 2	Option 3	Stamp & Signature of Members of the Syndicate/Sub Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder
	No. of Equity Shares					
	Bid Price (₹)					
	Amount Blocked (₹ in figures)					Acknowledgement Slip for Bidder
	ASBA Bank A/c No./UPI ID					
Bank Name & Branch					Bid cum Application Form No.	

Important Note: Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

ABH HEALTHCARE LIMITED 1

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS
DATED AUGUST 13, 2026 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

BIDDER'S UNDERTAKINGS AND CONFIRMATIONS FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL THE JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE ISSUE OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the RHP dated August 13, 2026 filed with the Registrar of Companies, Chandigarh (the "RoC"), I/We hereby confirm that I am/we are eligible person(s) to invest in the Issue in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/We agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP, Abridged Prospectus the GID, the Bid cum Application Form and other applicable laws. I/We undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/We acknowledge that in case of QIB Bidders, only the SCSBs and the BRLM and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas they have a right to reject it from Non-Institutional Bidders and Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP as applicable. I/We authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Issue. I/We confirm that I/we have read the RHP. My / our investment decision is solely based on the RHP as applicable and the Abridged Prospectus.

I/WE CONFIRM THAT: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity shares as nominees of any person resident outside India or foreign nationals or I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity shares on my/our own behalf through NRO account on non-repatriation basis. I/We represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) I/We have read the RHP and that my/our investment decision is based solely on the RHP (B) I/We have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures-Disclaimer in respect of Jurisdiction" in the RHP (C) the Equity Shares issued in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act; (D) I was/were outside of the United States at the time the Issue of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/we signed this Bid cum Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I am / we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (I) if I am / we are making an application to acquire any of the Equity shares for one or more managed accounts, I am /we are authorized in writing by each such managed account to subscribe to the Equity shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Members of the Syndicate (in Specified Locations) only or the Sub Syndicate Members or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or the RTAs (at Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Issue, including uploading our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSB as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Issue Account on receipt of instruction from Registrar to the Issue or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Issue or Sponsor Bank, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB/Registrar to the Issue shall reject the application. 3) I/We hereby authorise the Members of the Syndicate (in Specified Locations) only or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/We hereby provide our consent to the Stock Exchange / Sponsor Bank / NPCI / Registrar to the Issue for collecting, storing and using validating our PAN details from the bank account where my / our amount is blocked by the relevant SCSBs.

I/We acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Issue. I am/We are not an OCB. For further details, see "Issue Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on pages 272 and 308 respectively of the RHP.

INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an 'indication to make an Application' during the Bid/Issue period by a Bidder and not 'an Issue'.
- The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Issue will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor sub syndicate member nor the Registered Brokers nor the Registrar to the Issue nor RTAs/CDPs nor the SCSBs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The Price Band and the minimum Bid Lot has been decided by our Company in consultation with the Book Running Lead Manager. Price Band is Rs. 96/- to Rs. 102/- per Equity Share. The floor price is 9.6 times of the face value and the cap price is 10.2 times of the face value. Minimum Bid Lot is 2,400 Equity Shares and in multiples of 1,200 Equity Shares thereafter. The Bid/Issue period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. In case of revision of the Price Band the Bid/Issue Period will be extended for at least one additional working day subject to the total Bid/Issue Period not exceeding 10 working days. Any revision in the Price Band and the revised Bid/ Issue Period, if applicable, will be widely disseminated by notification to the Stock exchange, by issuing a press release and also by indicating the changes on the Website of the BRLM and on the terminals of the Syndicate Members.
- Maximum and Minimum Bid Size:** In case of Individual Bidders, such number of Equity Shares for a minimum application size of two lots wherein amount exceeds ₹ 200,000. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Bidders using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centres. In accordance with applicable law and SEBI UPI Circulars, Bidders to please ensure that SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c. are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Non-Institutional Investors Bidding for an amount exceeding ₹ 5,00,000 cannot use UPI Mechanism. UPI bidders applying up to ₹ 5,00,000 can apply as per NPCI vide circular reference no. NPCI/UP/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022. SEBI circular no. SEBI/HO/CFD/PoD-I/P/CIR/2024/0154 dated November 11, 2024.
 - For UPI Bidders bidding through the UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for public Issues.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that: (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders with application size up to ₹ 5,00,000 bidding through the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID belonging to any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 272 of the RHP.
- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form / Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that Members of the Syndicate, sub syndicate member, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchange do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 and press release dated March 28, 2023 and any subsequent press releases in this regard. You may be sent the RHP and the Abridged Prospectus either in physical form or electronic form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in it or accompanied in it.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act, and in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those Issue and sales occur.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in "Other Regulatory and Statutory Disclosures" and "Issue Procedure" on pages 247 and 272 of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP together with the terms and conditions contained therein.

Note: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP, as applicable. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLM and the Stock Exchange.

TEAR HERE

	COMPANY CONTACT DETAILS	REGISTRAR TO THE ISSUE
- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Issue. - In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB. - In case of queries related to upload of Bids submitted to the relevant Members of the Syndicate / RTAs / Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary. - For UPI related queries, investors can contact NPCI at the toll free number:- 18001201740 and Mail Id: ipo.upi@npci.org.in and the Registrar to the Issue at Tel: +91 22 6263 8200; E-mail: ipo@bigshareonline.com - In case of ASBA Bidders (other than 3-in-1 Bids) for a bid above ₹ 5,00,000, ensure that the bid is uploaded only by the SCSBs - Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. on the Bid/ Issue Closing Date.	ABH HEALTHCARE LIMITED Corporate Identity Number: U85300PB2021PLC052886 Anil Baghi Road, Ferozepur, Punjab - 152002, India. Tel No.: +91 7888690018 E-mail: investor@anilbaghihospital.com Website: www.abhhealthcare.org Contact person: Mr. Rahul Sharma, Company Secretary & Compliance Officer	Bigshare Services Private Limited Office no. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai-400093, Maharashtra, India. Tel No: +91 22 6263 8200 E-mail Id: ipo@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Id: investor@bigshareonline.com Contact Person: Mr. Sagar Pathare SEBI Registration No: INR000001385



(Please scan the QR Code to view the RHP)



ABRIDGED PROSPECTUS
100% Book Built Issue

ABH HEALTHCARE LIMITED
Corporate Identification Number: U85300PB2021PLC052886

REGISTERED OFFICE		CORPORATE OFFICE	CONTACT PERSON	EMAIL
Anil Baghi Road, Ferozepur, Punjab - 152002, India		N.A.	Mr. Rahul Sharma, Company Secretary & Compliance Officer	investor@anilbaghihospital.com
TELEPHONE / MOBILE NO.			WEBSITE	
+91 7888690018			www.abhhealthcare.org	
OUR PROMOTERS: DR. KAMAL BAGHI, DR. SAURABH BAGHI AND DR. VAISHALI SAINI				
DETAILS OF ISSUE TO PUBLIC				
Type	Fresh Issue Size	OFS size (by no. of shares or by amount in Rs)	Total Issue Size	Eligibility
Fresh Issue	Up to 34,29,600 Equity Shares aggregating up to ₹ [●] Lakhs.	N.A.	Up to ₹ [●] Lakhs	The Issue is being made pursuant to Regulation 229(2) of Chapter IX of SEBI (ICDR) Regulations and 253(1) of chapter IX of the SEBI (ICDR) Regulations, 2018 as amended. As the Company's post issue paid up capital is less than or equal to ₹1000.00 Lakhs.
OFFER FOR SALE AND THEIR AVERAGE COST OF ACQUISITION: NOT APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES				
RISK IN RELATION TO THE FIRST ISSUE				
This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹ 10/- each. The Floor Price, Cap Price and Issue Price to be determined by our Company in consultation with the Book Running Lead Manager on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process as stated in chapter titled “ <i>Basis for Issue Price</i> ” beginning on page 97 of the Red Herring Prospectus, should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.				
GENERAL RISKS				
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India (“ <i>SEBI</i> ”) nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of this Red Herring Prospectus. Specific attention of the investors is invited to the chapter titled “ <i>Risk Factors</i> ” beginning on page 29 of the Red Herring Prospectus.				
COMPANY’S ABSOLUTE RESPONSIBILITY				
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.				
LISTING				
The Equity Shares issued through this Red Herring Prospectus are proposed to be listed on the Emerge platform of National Stock Exchange of India Limited (“ <i>NSE EMERGE</i> ”), in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received “ <i>In-Principle</i> ” approval from the National Stock Exchange of India Limited for using its name in the Issue document for the listing of the Equity Shares, pursuant to letter dated December 1, 2025. For the purpose of the Issue, the Stock Exchange will be National Stock Exchange of India Limited.				
BOOK RUNNING LEAD MANAGER TO THE ISSUE				
Name and Logo		Contact Person	Email and Telephone	
 FEDEX SECURITIES PRIVATE LIMITED		Karuna Bangera/ Saipan Sanghvi	Email: mb@fedsec.in Tel. No.: +91 81049 85249	
REGISTRAR TO THE ISSUE				
Name and Logo		Contact Person	Email and Telephone	
 BIGSHARE SERVICES PRIVATE LIMITED		Mr. Sagar Pathare	Email: ipo@bigshareonline.com Tel. No.: +91 22 6263 8200	
ISSUE PROGRAMME*				
ISSUE OPENS ON: Monday August 24, 2026			ISSUE CLOSES ON ⁽¹⁾⁽²⁾ : Thursday, August 27, 2026	

1) Our Company, in consultation with the BRLM has decided that no participation by Anchor Investors will be considered in the IPO.

(2) Our Company, in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date, in accordance with the SEBI ICDR Regulation.

(3) The UPI mandate end time and date shall be at 5:00 p.m. on the Bid/Issue Closing Day.

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS



(Please scan this QR code to view the Red Herring Prospectus and the Abridged Prospectus.)

The following is a general summary of certain disclosures in the Red Herring Prospectus and the terms of the Issue and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Red Herring Prospectus, which is available at the websites of SEBI at www.sebi.gov.in, Emerge Platform of NSE Limited at www.nseindia.com the Company at www.abhhealthcare.org and Book Running Lead Manager www.fedsec.in.

References below are to page numbers of the Red Herring Prospectus dated August 13, 2026 Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the Red Herring Prospectus.

1. Summary of the primary business

Our core focus is on providing specialised tertiary medical care in Tier 3 cities, within the state of Punjab while seeking to strike a balance between providing quality healthcare services and affordability. We operate our hospital under the “Anil Baghi Hospital” brand, honoring the sacrifice of late Shri Anil Baghi. Located in Ferozepur, Punjab, our hospital has a capacity of 150 beds.

(a) Business Overview – Services Offered

Acquired by our Company in 2022, the hospital was established in 1985 with 30 (thirty) beds and is driven by a vision to provide affordable, accessible, and quality healthcare services, delivered with compassion. Since our acquisition, we have consistently invested in the hospital, expanding bed capacity, increasing our workforce, and introducing additional services and clinical specialties. As on the date of the Red Herring Prospectus, we have 150 (one hundred fifty) beds and offer 25 (twenty-five) medical specialties in our hospital.

(b) Industries Served and Typical Customers

Our extensive 35+ years of experience in the healthcare industry in the region where we operate has helped us develop a strong understanding of the region’s market dynamics. We have an extensive network of empanelment which includes, over 30 (thirty) private and public health insurance companies and third-party administrators. In addition to private health insurance, we are also empaneled with all major government insurance schemes available in this region, including Ex-Servicemen Contributory Health Scheme (ECHS), Railways, Food Corporation of India (FCI), Bharat Sanchar Nigam Limited (BSNL), and Ayushman Bharat - Sarbat Sehat Bima Yojana (AB-SSBY).

(c) Segment Reporting and Revenue Contribution.

The following table sets forth details of our Company’s revenue from inpatients by specialty (In Patient Department Services) for the periods indicated on standalone basis:-

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ in lakhs)	% of Revenue from Operations	Amount (₹ in lakhs)	% of Revenue from Operations	Amount (₹ in lakhs)	% of Revenue from Operations
Internal Medicine & Critical Care	2,674.52	52.40	2,070.43	42.33	1,787.32	43.19
Cardiology	261.45	5.12	477.52	9.76	437.64	10.58
Neurosurgery	181.69	3.56	243.46	4.98	283.93	6.86
General Surgery	272.97	5.35	233.58	4.78	229.91	5.56
Orthopedics , Trauma & Joint Replacement	269.85	5.29	240.93	4.93	258.80	6.25
Gastroenterology	28.44	0.56	93.04	1.90	77.32	1.87
Gynae & Obs	158.75	3.11	167.01	3.41	125.07	3.02
Urology & Lap Surgeon	99.36	1.95	111.12	2.27	91.63	2.21
Gastrointestinal Surgery	0.75	0.01	56.43	1.15	0.00	0.00
Neonatology	114.47	2.24	53.10	1.09	0.00	0.00
Nephrology & Dialysis	19.25	0.38	105.95	2.17	10.58	0.26
Neurology	26.54	0.52	67.68	1.38	68.01	1.64
Paediatrics	77.99	1.53	107.33	2.19	89.10	2.15
ENT	12.19	0.24	19.87	0.41	13.73	0.33
Oral Maxillofacial Surgery	7.29	0.14	2.83	0.06	2.47	0.06
Psychiatrist	5.76	0.11	6.28	0.13	0.16	0.00
Pulmonology	79.38	1.56	33.72	0.69	0.36	0.01
Anesthesiology	0.00	0.00	0.16	0.00	0.00	0.00
Total	4290.65	84.06	4090.44	83.62	3476.03	84.00

The following table sets forth our Company's standalone revenue split from inpatients between payor categories for the years indicated:

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ in lakhs)	% of Revenue from Operations	Amount (₹ in lakhs)	% of Revenue from Operations	Amount (₹ in lakhs)	% of Revenue from Operations
Govt. Schemes & PSUs	2,674.68	52.40	2,297.76	46.97	1,797.42	43.44
Insurance & TPAs	486.78	9.54	365.73	7.48	378.90	9.16
Self-Pay	1,625.74	31.85	1,971.50	40.30	1,762.16	42.58
Total	4,787.20	93.79	4,634.99	94.75	3,938.48	95.18

(d) Key Geographies

We derive almost all of our revenue from operations from our only hospital in Ferozepur, Punjab.

(e) Revenue Concentration Among Top 5 Customers

The % contribution of our Company's customers vis a vis standalone revenue from operations for the Fiscal 2026, Fiscal 2025, Fiscal 2024 are tabulated as follows:

Sr. No.	Name of customers*	Fiscal 2026		Fiscal 2025		Fiscal 2024	
		Amount (₹ in lakhs)	% contribution in the revenue	Amount (₹ in lakhs)	% contribution in the revenue	Amount (₹ in lakhs)	% contribution in the revenue
1.	Top 2 customers	2,169.73	42.51	1,720.12	35.16	1,444.01	34.90
2.	Top 5 customers	2,833.14	55.50	2,412.18	49.31	1,927.91	46.59
3.	Top 10 customers	3,019.02	59.15	2,556.66	52.27	2,081.10	50.29

*As on the date of the Red Herring Prospectus, we have not received consent from our customers

(f) Key Facilities

As on the date of the Red Herring Prospectus, we have 150 (one hundred fifty) beds and offer 25 (twenty five) medical specialties in our hospital such as, cardiac sciences, neurology, minimally invasive spine and brain surgeries, gastroenterology, laparoscopic and bariatric surgery, urology, pulmonology, nephrology, ENT, maxillofacial surgeries, obstetrics and gynecology, adult and neonatal critical care, orthopedics and joint replacement, neuro-psychiatry and drug de-addiction, general surgery, dentistry, physiotherapy and lab investigations and radiology.

(g) Business Strengths and Strategies

Strengths

- 1) Doctor led professional management team with proven execution capabilities
- 2) Delivering quality clinical care by attracting and retaining experienced and renowned clinicians
- 3) Diversified operations across clinical specialties, payor mix and hospitals
- 4) Comprehensive operating infrastructure including information technology and modern equipments
- 5) Track record of stable operating and financial performance and growth.

Strategies

- 1) Strengthen our current streams and expand into new and high-end clinical programs at our hospitals supported by latest technology
- 2) Continue to attract and retain qualified and experienced clinicians
- 3) Continue to upgrade our digital infrastructure to improve operational efficiencies and patient experience
- 4) Strengthening our presence and expanding our reach.

For further details, please refer chapter titled "**Business Overview**" beginning on page 125 of the Red Herring Prospectus.

2. Summary of the Industry

Healthcare has become one of India's largest sectors, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services, and increasing expenditure by public as well as private players.

India's healthcare delivery system is categorised into two major components - public and private. The government, i.e., the public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of Primary Healthcare Centers (PHCs) in rural areas. The private sector provides the majority of secondary, tertiary, and quaternary care institutions with a major concentration in metros, tier-I, and tier-II cities.

For further details, please refer chapter titled, **“Industry Overview”** beginning on page 110 of the Red Herring Prospectus.

Details of our Promoters

1) **Dr. Kamal Baghi** is one of the Promoters and Whole-time Director of the Company. He is also the Chairman of our Board. He holds a master's degree of medicine from Guru Nanak Dev University. He has been associated with our Company since January 1, 2022. Dr. Kamal Baghi founded Anil Baghi Hospital in 1985 and was also the founding member of Anil Baghi School of Nursing, Genesis Institute of Dental Sciences & Research, a postgraduate dental college and also Anil Baghi College of Nursing. He is an active member of the Federation of Indian Chambers of Commerce and Industry (FICCI) Healthcare Committee. Further, he was elected as a fellow of I.M.A. Academy of Medical Specialities in cardiology. He has around 4 (four) decades of experience in the healthcare sector and is currently responsible for the overall management of the Company.

2) **Dr. Saurabh Baghi** is one of the Promoters and Managing Director of our Company. He holds a bachelor's degree of medicine and surgery from 'Baba Farid University of Health Sciences'. He is a distinguished non-invasive cardiologist, academician, and healthcare professional with a career dedicated to advancing cardiovascular care and medical education. He earned his MD in Internal Medicine at The Brooklyn Hospital Center in Brooklyn, USA, where he developed a strong foundation in clinical excellence and patient care. Further honing his expertise, he pursued a fellowship in cardiology and heart failure at Mt. Sinai Hospital in New York, USA. In 2014, after completing his fellowship, Dr. Baghi joined Parkview Medical Center in Colorado as a Consultant Cardiologist. He has an experience of around 10 (ten) years in the field of healthcare sector and is currently responsible for handling the overall management of the Company.

3) **Dr. Vaishali Saini** is one of the Promoters and Non-Executive Director of our Company. She holds bachelor's degree of medicine and surgery from 'Baba Farid University of Health Sciences'. Dr. Vaishali Saini is an ABPN-Certified (American Board of Neurology and Psychiatry) Neurologist. She completed her Neurology training at the New York Presbyterian Hospital – Cornell Campus. After completing her training in 2014, she joined Parkview Medical Center in Colorado, USA, as the Director for stroke, where she led the development and management of their Stroke Program. Her leadership in this role contributed to improved stroke outcomes and the implementation of evidence - based practices in stroke management. She has around 5 (five) years of experience in the healthcare sector and currently oversees the hiring and training of nursing staff, ensuring NABH standards in patient care.

For further details, please refer chapter titled, **“Our Management” and “Our Promoters and Promoter Group”** beginning on page 158 and 173 respectively of the Red Herring Prospectus.

3. Objects of the issue

The Net Proceeds are currently expected to be deployed in accordance with the details provided in the table below:

Particulars	Estimated Amount (₹ in Lakhs) [#]
Repayment/prepayment, in part or full, of certain of our borrowings	1,700.00
Funding our working capital requirements	500.00
Funding inorganic growth through unidentified acquisitions and general corporate purposes [#]	[•]
Total*	[•]

[#] The cumulative amount to be utilized towards funding inorganic growth through unidentified acquisitions and general corporate purposes shall not exceed 35% of the Gross Proceeds as per Regulation 230 of SEBI ICDR Regulations. Further, the amount utilized for funding inorganic growth through unidentified acquisitions shall not exceed 25% of the Gross Proceeds. In addition, the amount to be utilized towards general corporate purposes alone shall not exceed 15% of the Gross Proceed or ₹ 1,000.00 lakhs whichever is lower.

*To be finalised upon determination of the Issue Price and updated in the Prospectus prior to filing with the RoC.

For further details, please refer to the chapter titled **“Objects of the Issue”** beginning on page 86 of the Red Herring Prospectus.

4. Pre and Post- issue shareholding of our Promoters, members of the Promoter Group and top 10 Shareholders

The aggregate shareholding, of each of the (i) Promoter(s), (ii) members of the Promoter Group and (iii) top 10 Shareholders (other than the Promoter and Promoter Group) as on the RHP and as at allotment as per the below mentioned format:

Sr. No	Pre- Issue Shareholding			Post-Issue shareholding as at Allotment			
	Name of Shareholders	Number of Equity Shares (2)	Shareholding(%)	At the Lower end of the Price Band (₹ [●])		At the Upper end of the Price Band (₹[●])	
				Number of Equity Shares ⁽²⁾	Shareholding(%)	Number of Equity Shares ⁽²⁾	Shareholding (%)
Promoters (A)							
1.	Dr. Saurabh Baghi	54,80,000	68.50	[●]	[●]	[●]	[●]
2.	Dr. Kamal Baghi	23,99,984	30.00	[●]	[●]	[●]	[●]
3.	Dr. Vaishali Saini	1,20,000	1.50	[●]	[●]	[●]	[●]
	Total (A)	79,99,984	100.00	[●]	[●]	[●]	[●]
Promoter Group (B) ⁽¹⁾							
1.	Mr. Hemraj Saini	4	0.00	[●]	[●]	[●]	[●]
2.	Mrs. Rita Saini	4	0.00	[●]	[●]	[●]	[●]
3.	Mrs. Sukarma Khanna	4	0.00	[●]	[●]	[●]	[●]
	Total (B)	12	0.00	[●]	[●]	[●]	[●]
	Top 10 Shareholders (other than A & B above)						
1.	Mr. Pradeep Khanna^	4	0.00	[●]	[●]	[●]	[●]
	Total (C)	4	0.00	[●]	[●]	[●]	[●]
	Other Shareholders (other than A, B & C above)						
N.A							
	Total (D)	N.A	N.A	[●]	[●]	[●]	[●]
	Grand Total (A+B+C+D)	80,00,000	100.00	[●]	[●]	[●]	[●]

Subject to finalization of Basis of Allotment

[^] Mr. Pradeep Khanna is the spouse of Mrs. Sukarma Khanna, a member of the Promoter Group

Notes:

(1) The Promoter Group shareholders are Mr. Hemraj Saini, Mrs. Rita Saini and Mrs. Sukarma Khanna

(2) Includes all transfers of Equity Shares by existing shareholders.

(3) Based on the Issue price of ₹ [●] and subject to finalization of the basis of allotment

For further details, please refer chapter titled “**Capital Structure**” beginning on page 76 of the Red Herring Prospectus.

5. Summary of Restated Consolidated Information

The following information has been derived from our Restated Consolidated Financial Information for the Financial Years ended March 31, 2026, March 31, 2025, March 31, 2024

(₹ in lakhs)

Particulars	For the Financial Year ended		
	March 31, 2026	March 31, 2025	March 31, 2024
Equity Share capital	800.00	200.00	200.00
Net Worth	1,726.54	1,160.22	629.53
Revenue from Operations	5,250.69	4,926.71	4,138.02
EBITDA	1,471.65	1,319.51	689.28
Restated Profit / (Loss) after tax	563.94	534.70	165.56
- Basic Earning per Equity Share	7.05	6.68	2.07
Diluted Earning per Equity Share	7.05	6.68	2.07
Return of Equity	39.07	59.75	30.33
Return on Net Worth	39.07	59.75	30.33
Net Asset Value per Equity Share	21.58	14.50	7.87
Total Borrowings	5,516.38	4,197.93	3,582.68
Cash flow from operating activities	211.07	354.42	88.81
Cash flow from investing activities	(914.30)	(453.41)	(1,306.27)
Cash flow from financing activities	944.80	158.48	1,203.91

For further details, please refer chapter titled “**Basis for Issue Price**”, “**Restated Consolidated Financial Information**” and “**Management’s Discussion and Analysis of Financial Condition and Results of Operations**” on pages 97, 178 and 216 respectively, of the Red Herring Prospectus.

6. Summary of Key Performance Indicators:

Details of the KPIs for the Financial Years ended March 31, 2026, March 31, 2025, March 31, 2024 (on Consolidated basis).

Particulars	As at March 31, 2026	As at March 31, 2025	As at March 31, 2024
Revenue from Operations (₹ in lakhs)	5,250.69	4,926.71	4,138.02
Growth in Revenue from Operations (%) ⁽¹⁾	6.58	19.06	39.75
EBITDA (₹ in lakhs) ⁽²⁾	1,471.65	1,319.51	689.28
EBITDA Margin (%) ⁽³⁾	28.03	26.78	16.66
Restated Profit after Tax (₹ in lakhs)	563.94	534.70	165.56
PAT Margin (%) ⁽⁴⁾	10.74	10.85	4.00
Net Worth (₹ in lakhs) ⁽⁵⁾	1,726.54	1,160.22	629.53
Capital Employed (₹ in lakhs)	7,430.49	5,488.98	4,284.64
ROE (%) ⁽⁶⁾	39.07	59.75	30.33
ROCE (%) ⁽⁷⁾	19.09	22.70	14.96
Debt - Equity Ratio ⁽⁸⁾	3.20	3.62	5.69
Fixed Assets Turnover Ratio ⁽⁹⁾	1.25	1.35	1.23

* Not Annualized

Notes:

Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.

1) Growth in Revenue from Operations (%) is calculated as Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.

2) EBITDA is calculated as Restated Profit before tax + Depreciation & amortisation + Interest expenses – Other Income

3) EBITDA Margin (%) is calculated as EBITDA divided by Revenue from Operations

4) PAT Margin (%) is calculated as PAT for the period/year divided by revenue from operations.

5) Net worth is aggregate value of the paid-up equity share capital of the Company and all reserves created out of the profits, securities premium account and debit or credit balance of profit and loss account, excluding revaluation reserves if any, as per Restated Financial Statements.

6) Return on Equity (%) refers to restated profit for the year/period attributable to equity shareholders of our Company divided by Shareholder Equity.

7) Return on Capital Employed is calculated as earnings before interest and taxes divided by Capital Employed. Capital Employed is calculated as total equity plus total borrowings and deferred tax liabilities minus intangible assets.

8) Debt Equity Ratio: This is defined as total debt divided by total equity.

9) Fixed Asset Turnover Ratio: This is defined as revenue from operations divided by total of net block property, plant & equipment.

-Earnings before interest and tax is calculated as restated profit / (loss) for the period / year before tax plus finance costs reduced by other income.

For further details, please refer chapter titled “**Management’s Discussion and Analysis of Financial Condition and Results of Operations**” beginning on page 216 of the Red Herring Prospectus.

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the Red Herring Prospectus:

1. Our Company has been specifically formed for the purpose of acquisition of the business of M/s. Anil Baghi Hospital (sole proprietorship concern of one of our Promoters), thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects.
2. Our revenues are significantly dependent on our only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect our business, financial condition and results of operations.
3. If we are unable to keep pace with technological changes, new equipments and service introductions, changes in patients’ needs and evolving industry standards as well as failure or malfunction of our medical or other equipments, our business and financial condition may be adversely affected.
4. We rely on certain third parties, including suppliers, and also enter into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, non-renewal or any breach of the conditions of such contracts could have a material adverse impact on our business, financial condition and results of operations.
5. We operate in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect our business, results of operations and cash flows.
6. Our Company has acquired M/s. Anil Baghi Hospital, the sole proprietorship concern of one of our Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to our limited past experience in businesses.
7. We are significantly dependent on our key personnels, including our Promoters, Dr. Kamal Baghi, Dr. Saurabh Baghi, Dr. Vaishali Saini, senior management and other healthcare professionals and any loss of or our inability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.

8. The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
9. We do not own the premises where our Registered office and hospital are located. Any adverse event that requires us to vacate the said property may materially adversely affect our business operations and financial conditions.
10. We have a high debt-equity ratio and may face certain funding risks. Any further increase in borrowings may have a material adverse effect on our business, financial condition and results of operations. Further, if we do not generate sufficient amount of cash flow from operations, our liquidity and ability to service our indebtedness could be adversely affected.

For further details, please refer chapter titled “**Risk Factors**” beginning on page 29 of the Red Herring Prospectus

9. The details of weighted average cost of acquisition of shares of our promoters

Name of the Promoters	Number of Equity Shares acquired in the one year preceding the date of the Red Herring Prospectus**	Weighted Average Cost of Acquisition per Equity Share (in ₹)*
Dr. Saurabh Baghi	Nil	N.A.
Dr. Kamal Baghi	Nil	N.A.
Dr. Vaishali Saini	Nil	N.A.

* As certified by our Statutory Auditor M/s. G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 13, 2026.

**The face value of Equity Shares is ₹10/- each

WEIGHTED AVERAGE COST OF ACQUISITION OF ALL EQUITY SHARES TRANSACTED IN THE PRECEDING THREE (3) YEARS, EIGHTEEN (18) MONTHS AND ONE (1) YEAR

Period	Weighted average cost of acquisition per Equity Share (in ₹)*	Issue Price (₹ [●]) is ‘X’ times the weighted average cost of acquisition**	Range of acquisition price per Equity Share: lowest price – highest price (in ₹)**
Last three (3) years	Negligible	N.A.	Nil-33
Last eighteen (18) months	N.A.	N.A.	N.A.
Last one (1) year	N.A.	N.A.	N.A.

* As certified by our Statutory Auditor M/s. G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 13, 2026.

**The face value of Equity Shares is ₹10/- each

For further details, please refer to the chapter titled “**Capital Structure**” beginning on page 76 of the Red Herring Prospectus

10. Board of Directors and Key Managerial Personnel

The names and designation of members of the Board of Directors and Key Managerial Personnel are set out below:

Sr No.	Name of Directors and Key Managerial Personnel	Designation
Board of Directors		
1.	Dr. Kamal Baghi	Chairman and Whole-time Director
2.	Dr. Saurabh Baghi	Managing Director
3.	Dr. Vaishali Saini	Non-Executive Director
4.	Dr. Satnam Singh Nijjar	Non- Executive Independent Director
5.	Mr. Balwinder Singh	Non- Executive Independent Director
Key Managerial Personnel		
1.	Mr. Rahul Sharma	Company Secretary and Compliance Officer
2.	Mr. Rajeev Agarwal	Chief Financial Officer

For further details, please refer to the chapter titled “**Our Management**” beginning on page 158 of the Red Herring Prospectus.

11. Auditor Qualifications:

There are no qualifications, reservations and adverse remarks by our Statutory Auditors in the Restated Consolidated Financial Information.

12. Summary table of outstanding litigations

Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount Involved (₹ in Lakhs)^
Company						
By the Company	Nil	Nil	1	N.A.	Nil	18.57
Against the Company	Nil	3	Nil	N.A.	3	24.74
Directors (other than Promoters)						
By our Directors	Nil	Nil	Nil	N.A.	1	0.20
Against the Directors	Nil	1	Nil	N.A.	Nil	0.31
Promoters						
By Promoters	Nil	Nil	Nil	Nil	3	42.16
Against Promoters	Nil	6	Nil	Nil	5	259.31
Key Managerial Personnel (KMP) / Senior Management Personnel (SMP)						
By KMPs / SMPs	Nil	Nil	Nil	Nil	Nil	Nil
Against our KMPs/ SMPs	Nil	Nil	Nil	Nil	Nil	Nil
Controlled entities						
By Controlled entities	Nil	Nil	Nil	Nil	Nil	Nil
Against Controlled entities	Nil	2	Nil	Nil	Nil	0.05

^ Rounded off to closest decimal.

For further details, please refer chapter titled “*Risk Factors*” and “*Outstanding Litigation and Material Developments*” beginning on pages 29 and 236 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("US Securities Act") or any other state securities laws in the United States of America and may not be sold or offered within the United States of America, or to, or for the account or benefit of "US Persons" as defined in Regulation S of the U.S. Securities Act, except pursuant to exemption from, or in a transaction not subject to, the registration requirements of US Securities Act and applicable state securities laws.

Accordingly, the equity shares are being offered and sold only outside the United States of America in an offshore transaction in reliance upon Regulation under the US Securities Act and the applicable laws of the jurisdiction where those offers and sale occur.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Bidders are advised to ensure that any Bid from them does not exceed investment limits or the maximum number of Equity Shares that can be held by them under applicable law. Further, each Bidder where required must agree in the Allotment Advice that such Bidder will not sell or transfer any Equity Shares or any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than in accordance with applicable laws.

13. DECLARATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 1956, the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS DATED AUGUST 13, 2026 (RHP)

BIDDER'S UNDERTAKINGS AND CONFIRMATIONS FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of Sole Bidder / First Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an Issue' and not 'an Issue'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Bidders shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment Amount exceeds ₹ 2,00,000), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. If, however, the Bidder does not either revise the Bid or make additional payment and the Issue Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked. In case of a downward revision in the Price Band, announced as above could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of Sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c. are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Bidding for an amount exceeding ₹ 5,00,000 cannot use UPI Mechanism. UPI bidders applying up to ₹ 5,00,000 can apply as per NPCI vide circular reference no. NPCI/UIP/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022 and SEBI circular no. SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024.
 - For UPI Bidders bidding through the UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders with application size up to ₹ 5,00,000 bidding through the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID belonging to any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 272 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate/ sub syndicate member/ SCSBs/ Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- For Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with the CBDT notification dated February 13, 2020 and the subsequent press releases, including press release dated June 25, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022 read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ISSUE STRUCTURE

This Issue is being made by way of Book Building Process.

Particulars	Market Maker Reservation Portion	QIBs	Non-Institutional Bidders	Individual Investors
Number of Equity Shares available for allocation ⁽¹⁾	Upto 1,72,800 Equity Shares of face value of ₹10/-each	Not more than 1,99,200 Equity Shares of face value of ₹10 each	Not less than 15,28,800 Equity Shares of face value of ₹ 10 each available for allocation or Issue less allocation to QIB Bidders and Individual investors	Not less than 15,28,800 Equity Shares of face value of ₹ 10 each available for allocation or Issue less allocation to QIB Bidders and Non-Institutional Bidders
Percentage of Issue Size available for allocation	5.04% of the Issue size	Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, 5% of the Net QIB Portion shall be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion	Not less than 15% of the Net Issue subject to the following :- a) One- third of the portion available to non-Institutional Investors shall be reserved for Bidders with application size of more than two lots and up to such lots equivalent to not more than ₹ 10.00 lakhs; b) two-third of the portion available to non-Institutional Investors shall be reserved for Bidders with application size of more than ₹ 10.00 lakhs;	Not less than 35% of the Net Issue.
Basis of Allotment/ Allocation if respective category is versubscribed	Firm Allotment	Proportionate as follows: a) 10,800 Equity Shares of face value of ₹ 10 each shall be available for allocation on a proportionate basis to Mutual Funds only; and b) 1,88,400 Equity Shares of face value of ₹ 10 each shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above.	Subject to the availability of shares in non-institutional investors' category, the allotment of equity shares to each non institutional category shall not be less than the minimum application size in non-institutional investor category, and the remaining shares, if any, shall be allotted on a proportionate basis.	Allotment to each Individual Investors shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Individual Investors portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details see, "Issue Procedure" on page 272 of the Red Herring Prospectus
Mode of Bid	Only through the ASBA Process	Only through the ASBA Process	Through ASBA Process	Through ASBA Process through banks or by using UPI ID for payment
Minimum Application Size	1,72,800 Equity Shares of face value of ₹10/-each	Such number of Equity Shares and in multiples of [●] Equity Shares that the Bid Application exceeds two lots		Such number of Equity Shares in two lots so that the Bid Amount exceeds ₹ 2.00 lakhs
Maximum Application Size	1,72,800 Equity Shares of face value of ₹10/-each	Such number of Equity Shares in multiples of [●] Equity Shares of face value of ₹10/- each not exceeding the size of the Net Issue, subject to applicable limits	Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Issue (excluding the QIB portion), subject to limits as applicable to the Bidder	Such number of Equity Shares in two lots so that the Bid Amount exceeds ₹ 2.00 lakhs
Mode of allotment	Compulsorily in dematerialized mode			
Trading Lot	[●] Equity Shares of face value of ₹10/-each, however, the Market Maker may accept odd lots if any in the market as required under the SEBI ICDR Regulations	[●] Equity Shares of face value of ₹10/- each and in multiples thereof	[●] Equity Shares of face value of ₹10/- each and in multiples thereof	[●] Equity Shares of face value of ₹10/- each and in multiples thereof
Who can Apply ⁽¹⁾	Market Maker	Public financial institutions as specified in Section 2(72) of the Companies Act 2013, scheduled commercial banks, multilateral and bilateral development financial institutions, mutual funds registered with SEBI, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs, registered with SEBI, state industrial development corporation, insurance company registered with IRDAI, provident fund with minimum corpus of ₹ 2500 lakhs, pension fund with minimum corpus of ₹ 2500 lakhs, National Investment Fund set up by the Government of India, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important NBFCs, in accordance with applicable laws including FEMA Rules	Resident Indian individuals, Eligible NRIs, HUFs (in the name of Karta), companies, corporate bodies, scientific institutions, societies, family offices, trusts, FPIs who are individuals, corporate bodies and family offices	Resident Indian individuals, HUFs (in the name of Karta) and Eligible NRIs applying for Equity Shares so that the Bid Amount shall be above two lots, accordingly, the minimum application size shall be above ₹ 2.00 Lakhs.
Terms of payment ⁽²⁾	Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form.			

(1) In terms of Rule 19(2) of the SCRR read with Regulation 252 of the SEBI (ICDR) Regulations, 2018 this is an Issue for at least 25% of the post Issue paid-up Equity share capital of the Company. This Issue is being made through Book Building Process, wherein allocation to the public shall be as per Regulation 252 of the SEBI (ICDR) Regulations.

(2) Subject to valid Bids being received at or above the Issue Price, undersubscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the Book Running Lead Manager and the Stock Exchange, subject to applicable laws.

The Bids by FPIs with certain structures as described under "Issue Procedure - Bids by FPIs" on pages 272 of the Red Herring Prospectus and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.

If the Bid is submitted in joint names, the Bid cum Application form should contain only the name of the first Bidder whose name should also appear as the first holder of the depository account held in joint names. The signature of only the first Bidder would be required in the Bid cum Application form and such first Bidder would be deemed to have signed on behalf of the joint holders. Bidders will be required to confirm and will be deemed to have represented to our Company, the Underwriters, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable law, rules, regulations, guidelines and approvals to acquire the Equity Shares.

This Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018. For further details, see "Issue Procedure" on page 272 of the Red Herring Prospectus.

